The STAT+ article looks at IPOs, GLP-1 drugs and the challenges of gene therapy in biotech. GLP-1 agonists have systemic effects including renal effects via receptors in the kidney, leading to diuretic and natriuretic effects via tubular cells and sodium transporters[1]. Preclinical studies show that incretin therapy reduces albuminuria, affects glomerulosclerosis, oxidative stress and fibrosis in the kidney[1]. Diabetic nephropathy is the main cause of kidney failure, and in case of renal insufficiency, the possibilities of safe diabetes compensation are limited[1]. Therapy with GLP-1 receptor agonists in patients with type 2 diabetes and nephropathy is effective in terms of both efficacy and safety[1]. In the treatment of obesity, GLP-1 requires integrated care including screenings, management of gastrointestinal side effects, prevention of nutrient deficiencies, muscle and bone loss[2]. A joint opinion of professional societies recommends nutritional and lifestyle priorities to improve the effectiveness, safety and sustainability of this therapy[2].